…..Behe just placed a major thumping on the head of Sean Carroll on pyrimethamine in a back and forth at Science for the full story see: http://www.amazon.com/gp/blog/A3DGRQ0IO7KYQ2No, Behe just put together a series of non-sequiturs. To put this in perspective, here is what Carroll wrote: (which flows on from this article )
"With respect to the latter, the passage he quotes in his Letter about how "[a]dding more mutations …. can increase the level of resistance" is immediately followed in his book by the disclaimer that "[h]owever, as usual there's a hitch. Some of those extra mutations (but not the first one) seem to interfere with the normal work of the protein" (p. 75). Behe is clearly seeking to convey the message that there is some impediment to Darwinian evolution via multiple intermediates, both in this specific case and in general (hence the phrase "as usual"). However, this is not the case. Careful inspection of the data in the reference I cited (2 (Sirawaraporn et al., 1997)) reveals that, in fact, certain mutations (e.g., Cys59->Arg) increase specific parameters of the enzyme's performance. Structural studies suggest that this mutation, found at very high frequency in drug-resistant parasites in nature, improves enzyme binding to substrates in the context of otherwise adverse mutations (3(Yuvaniyama et al., 2003)). Furthermore, pyrimethamine resistant dihydrofolate reductase enzymes actually have activities equal to or better than the wild-type enzyme (4(Sandefur et al., 2007)). Behe also neglects to note the fact that such triple and quadruple mutant enzymes have been found in isolates from India, Southeast Asia, Eastern Africa, and South America, including areas where pyrimethamine use has been limited. The latter suggests that mutant parasites may be as fit as wild-type parasites."What Behe writes in response:
"Carroll’s beef is that several papers he cites (W. Sirawaraporn et al., Proc. Natl. Acad. Sci. U.S.A. 94, 1124 (1997); J. Yuvaniyama et al., Nat. Struct. Biol. 10, 357 (2003); C. I. Sandefur, J. M. Wooden, I. K. Quaye, W. Sirawaraporn, C. H. Sibley, Mol. Biochem. Parasitol. 154,1 (2007)) have shown that, in the laboratory, in some respects intermediate mutations in the enzyme-target of pyrimethamine have better activity than the wild-type enzyme. But this data proves too much. If the mutations improve the enzyme in vitro, then that begs the question of why organisms with these mutations don’t outcompete the wild type in nature, even in the absence of pyrimethamine."This is a clear example of misdirection. Firstly, the context is clearly is whether the extra mutations that increase the resistance of the malarial parasites are deleterious to enzyme activity, and whether further increases in resistance can only be supported if two subsequent mutations occur together (Behe's claim, pg 75 EoE), or if all the mutations increase fitness in a stepwise fashion (Carroll's claim), not whether Behe made any mention of pyrimethamine resistance at all. As it happens, the data support Carroll, experiments in enzyme activity clearly show that mutations in the enzyme-target of pyrimethamine result in step-wise increases in resistance, with no detrimental effect on the enzyme activity (even a modest increase in activity).
| Mutation | Enyme activity vs wild type | increase of resistance vs wild type |
| S108N | similar | 10x |
| S108N+N51I | 2x | 20x |
| N51I+ C59R+S108N | 2x | 100x |
| N51I+C59R+S108N+I164L | 2x | 700x |
"One possibility, which plagues all in vitro work, is that perhaps the mutants have other, detrimental aspects, not measured in an assay, which makes the alteration a net burden in the wild. If that is the case, then the mutant enzyme might run rings around the wild-type enzyme when both are in a test tube in a lab, but could still be a bust in nature. "Unfortunately for Behe, the fitness of the double and triple mutants have been measured in the field, and the S108N+N51I and N51I+ C59R+S108N mutants are more fit than the wild type (Roper et al., 2003). Behe asks why "organisms with these mutations don’t outcompete the wild type in nature, even in the absence of pyrimethamine". Well, they do. In Tanzania, resistant malarial parasites spread into areas where no drug was being used, up to 150 miles away from drug using villages (Clyde & Shute 1957). In South-East Asia, the triple resistant mutants are still highly prevalent, decades after pyrimethamine use has been discontinued (Sanderfur et al., 2007). The same pattern is seen around the world, where pyrimethamine is discontinued, very many years later, the wild type has still not displaced the mutant parasites. The mutant enzyme is running rings around the wild-type enzyme in the wild. In the paper Behe cites as hypothesizing that multiple simultaneous mutations (Nair et al., 2003), he fails to note that this was one of three hypotheses presented in that paper (selective bottlenecks, small effective population size were the two others), and the multiple mutations hypothesis was based on an incorrect fitness estimate for multiple mutations (see Sanderfur et al., 2007). As well, pyrimethamine resistance develops very rapidly, 6 years from the first appearance of resistance to fixation of 3 or 4 mutation-bearing enzymes is typical (Sanderfur et al., 2007, Talisuna et al., 2004). This is not consistent with the need for simultaneous double mutations (Talisuna et al., 2004). Thus once again, Behe misdirects and misleads by only selectively reporting or interpreting data, or failing to understand the data. Carroll has it right; acquisition of pyrimethamine resistance is an example of stepwise accumulation of beneficial mutations. References:
Carroll S, Science 316, 1427 (2007)
Carroll S, Science 318, 196 (2007)
Clyde, DF, and Shute TG. Trans. R. Soc. Trop. Med. Hyg. 51: 505–513. (1957).
Nair S., et al., Mol. Biol. Evol. 20(9):1526–1536. (2003)
Roper, C., et al., Lancet 361, 1174–1181. (2003).
Sandefur CI, et al., Mol. Biochem. Parasitol. 154,1 (2007).
Sirawaraporn W, et al., Proc. Natl. Acad. Sci. U.S.A. 94,1124 (1997).
Talisuna, AO, et al., Clinical Microbiology Reviews, 17, p. 235–254 (2004).
Yuvaniyama J, et al., Nat. Struct. Biol. 10, 357 (2003).
21 Comments
SteveF · 24 October 2007
TomS · 24 October 2007
I have mixed feelings about this kind of discussion. Of course, I appreciate it that scientists are enlightening us about the realities concerning evolution. So I'm certainly not complaining. Yet the anti-evolutionists can only delight in the appearance that they have generated - the appearance that there is something substantive to ID that leads to scientific "controversy". Or, to put it another way, what connection is there between a (supposed, but not really existing) hypothesis of "intelligent design" and what Behe is claiming? How does Behe's claim differ from just yet another "gap in evolution". How does Behe's claim amount to support for an alternative hypothesis?
Frank J · 24 October 2007
noncarborundum · 24 October 2007
Henry J · 24 October 2007
Dale Husband · 24 October 2007
Paul Burnett · 24 October 2007
Henry J plaintively asked: "They want people to think that God intentionally designed parasites? I have yet to figure out why they seem to want people to think that."
To paraphrase biologist J B S Haldane, "God must have an inordinate fondness for parasites, because he created so many of them."
Glen Davidson · 24 October 2007
harold · 24 October 2007
Ian Musgrave · 24 October 2007
Mike Elzinga · 24 October 2007
Lino D'Ischia · 24 October 2007
snaxalotl · 25 October 2007
"thumping on the head"
this is the problem. it takes more than just good arguments because the true believers will watch one argument and report seeing a completely different one. Creationists. Can't live with 'em, can't kill 'em.
Nigel D · 25 October 2007
james · 25 October 2007
i dont mean to pour cold water on what is obviously a joke, but talking like that just allows religious fundamentalists to label freethinkers as "militant atheist fundamentalists" whilst providing them with a documented occurrence of death threats to use in their quote mines.
Nigel D · 25 October 2007
James, I see your point, but if the IDologists were going to construe what I wrote as a death threat, they could just as easily take anything else negative that I've said in the same vein. After all, their track record in twisting quotes so they mean the opposite of what the author intended is well known.
Torbjörn Larsson, OM · 25 October 2007
Torbjörn Larsson, OM · 25 October 2007
Um, two formal matters.
I have sometimes used italics for names, and it wasn't intended above as a marker for emphasis. [I will have to come up with a different praxis as it was confusing.]
And the quoted part of your answer above was to wamba.
hoary puccoon · 25 October 2007
harold wrote:
"From my perspective, the idea that malaria was designed because sinful humans deserve to suffer is outrageous, especially given the obvious fact that malaria infection is unrelated to sinfulness."
Actually, malaria deaths are disproportionately very young children. So, sinfulness is related to malaria infection-- They're negatively correlated.
Even if Behe's point were proved, and there really were an Intelligent Designer who took some kind of twisted pleasure in killing off little kids, is there any threat or any promise at all that could possibly make you want to worship such a being?
Andrew Wade · 25 October 2007
William Bradford · 14 November 2007
http://telicthoughts.com/behe-vs-caroll-reloaded/